Accessibility Menu
 
Aligos Therapeutics logo

Aligos Therapeutics

(NASDAQ) ALGS

Current Price$6.63
Market Cap$41.21M
Since IPO (2020)-98%
5 Year-99%
1 Year-28%
1 Month-7%

Aligos Therapeutics Financials at a Glance

Market Cap

$41.21M

Revenue (TTM)

$2.19M

Net Income (TTM)

$24.19M

EPS (TTM)

$-8.60

P/E Ratio

-0.77

Dividend

$0.00

Beta (Volatility)

1.43 (Average)

Price

$6.63

Volume

37,109.568

Open

$6.70

Previous Close

$6.56

Daily Range

$6.41 - $6.92

52-Week Range

$3.76 - $13.69

ALGS News

ALGS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Aligos Therapeutics

Industry

Biotechnology

Employees

82

CEO

Lawrence M. Blatt, PhD, MBA

Headquarters

South San Francisco, CA 94080, US

ALGS Financials

Key Financial Metrics (TTM)

Gross Margin

76%

Operating Margin

-40%

Net Income Margin

-11%

Return on Equity

-197%

Return on Capital

-1%

Return on Assets

-27%

Earnings Yield

-1.30%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$41.21M

Shares Outstanding

6.19M

Volume

37.11K

Short Interest

0.00%

Avg. Volume

55.45K

Financials (TTM)

Gross Profit

$1.26M

Operating Income

$87.98M

EBITDA

$87.06M

Operating Cash Flow

$82.50M

Capital Expenditure

$437.00K

Free Cash Flow

$82.94M

Cash & ST Invst.

$77.84M

Total Debt

$5.25M

Aligos Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$169.00K

-73.1%

Gross Profit

$88.00K

-114.0%

Gross Margin

-52.07%

N/A

Market Cap

$41.21M

N/A

Market Cap/Employee

$588.73K

N/A

Employees

70

N/A

Net Income

$19.88M

+75.8%

EBITDA

$21.56M

-8.4%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$72.70M

+49.7%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$1.52M

-69.0%

Short Term Debt

$3.73M

+7.7%

Return on Assets

-27.01%

N/A

Return on Invested Capital

-1.29%

N/A

Free Cash Flow

$21.84M

-18.5%

Operating Cash Flow

$21.75M

-18.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
XFORX4 Pharmaceuticals, Inc.
$3.99-1.24%
FGENFibroGen, Inc.
$9.07-1.63%
OKUROnKure Therapeutics, Inc.
$3.79-5.01%
INMBINmune Bio, Inc.
$1.14+1.79%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$165.17-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$8.52+0.03%
TQQQProShares Trust - ProShares UltraPro Qqq
$37.89-0.02%
MUMicron Technology
$321.80-0.10%

Questions About ALGS

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.